Horizon Pharma (HZNP) Stock Rating Upgraded by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Horizon Pharma (NASDAQ:HZNP) from a hold rating to a buy rating in a report published on Tuesday.

A number of other research analysts have also recently weighed in on the stock. Morgan Stanley boosted their target price on shares of Horizon Pharma from $16.00 to $24.00 and gave the company an equal weight rating in a research note on Friday, August 17th. BMO Capital Markets cut shares of Horizon Pharma from an outperform rating to a market perform rating and set a $18.00 target price on the stock. in a research note on Monday, August 6th. Piper Jaffray Companies set a $25.00 target price on shares of Horizon Pharma and gave the company a buy rating in a research note on Monday, September 24th. Goldman Sachs Group set a $26.00 target price on shares of Horizon Pharma and gave the company a buy rating in a research note on Thursday, October 4th. Finally, Cowen reiterated a buy rating and issued a $25.00 target price on shares of Horizon Pharma in a research note on Thursday, August 9th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $21.92.

Horizon Pharma stock opened at $19.07 on Tuesday. Horizon Pharma has a fifty-two week low of $12.55 and a fifty-two week high of $21.25. The stock has a market cap of $3.21 billion, a P/E ratio of 16.10, a PEG ratio of 1.22 and a beta of 1.40. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.17. Horizon Pharma had a negative net margin of 28.02% and a positive return on equity of 19.05%. The business had revenue of $302.84 million for the quarter, compared to analysts’ expectations of $275.51 million. During the same period in the previous year, the company earned $0.41 earnings per share. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, research analysts anticipate that Horizon Pharma will post 1.34 earnings per share for the current year.

In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of the business’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $20.63, for a total value of $204,319.52. Following the transaction, the executive vice president now directly owns 28,767 shares in the company, valued at $593,463.21. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of HZNP. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Horizon Pharma by 74.4% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 3,877 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in shares of Horizon Pharma in the second quarter valued at approximately $172,000. Strs Ohio raised its position in shares of Horizon Pharma by 74.2% in the second quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 4,600 shares during the period. Inspirion Wealth Advisors LLC bought a new stake in shares of Horizon Pharma in the second quarter valued at approximately $207,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in shares of Horizon Pharma in the second quarter valued at approximately $234,000. 86.84% of the stock is currently owned by institutional investors.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Further Reading: Day Trading

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Booking Holdings Inc.  Position Raised by Capital Research Global Investors
Booking Holdings Inc. Position Raised by Capital Research Global Investors
Capital Research Global Investors Reduces Stake in Netflix, Inc.
Capital Research Global Investors Reduces Stake in Netflix, Inc.
Capital Research Global Investors Sells 9,934,932 Shares of QUALCOMM, Inc.
Capital Research Global Investors Sells 9,934,932 Shares of QUALCOMM, Inc.
Capital International Sarl Purchases 2,000 Shares of Ryanair Holdings plc
Capital International Sarl Purchases 2,000 Shares of Ryanair Holdings plc
Plumas Bancorp  versus Asta Funding  Head-To-Head Analysis
Plumas Bancorp versus Asta Funding Head-To-Head Analysis
Analyzing Bergio International  & Charles & Colvard, Ltd.
Analyzing Bergio International & Charles & Colvard, Ltd.


© 2006-2018 Ticker Report